Abcuro 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  ABC008 / Abcuro
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL) (clinicaltrials.gov) -  Oct 28, 2024   
    P1/2,  N=21, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=30 --> 21 | Trial completion date: Dec 2025 --> Sep 2027 | Trial primary completion date: Dec 2024 --> Sep 2025
  • ||||||||||  ABC008 / Abcuro
    Enrollment open, Trial primary completion date:  Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis (clinicaltrials.gov) -  Oct 24, 2024   
    P2/3,  N=270, Recruiting, 
    Recruiting --> Active, not recruiting | N=30 --> 21 | Trial completion date: Dec 2025 --> Sep 2027 | Trial primary completion date: Dec 2024 --> Sep 2025 Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2028 --> Jan 2029
  • ||||||||||  ABC008 / Abcuro
    Enrollment change, Trial completion date, Trial primary completion date:  ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL) (clinicaltrials.gov) -  Sep 26, 2023   
    P1/2,  N=30, Recruiting, 
    Recruiting --> Active, not recruiting N=15 --> 30 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  ABC008 / Abcuro, Copiktra (duvelisib) / Secura Bio, Yakult Honsha
    KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas (ENMCC - 391-392) -  Nov 4, 2022 - Abstract #ASH2022ASH_5344;    
    Selective depletion of tumor cells with an anti-KLRG1 depleting mAb in specific subtypes of TCLs, T-LGLL, and CLPD-NK is effective in vitro and in vivo, and its combination with Duv has marked activity in an aggressive PTCL-NOS xenograft model. A multicenter phase I/II trial of the KLRG1 depleting antibody ABC008 (Abcuro) in patients with R/R T-LGLL has been initiated.